The University Of Dundee investment portfolio

Amphista Therapeutics develops next‑generation targeted protein‑degradation medicines, employing its proprietary “Targeted Glue” technology to create drugs that selectively destroy disease‑causing proteins. Its products are directed at patients with high‑unmet‑need diseases where conventional therapies are insufficient.

Platinum Informatics provides software platforms that enable the management, visualisation and analysis of large, complex data sets for laboratory and industrial environments, targeting life‑science research and related data‑intensive sectors.